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Background: Hypertension is a risk factor for cardiovascular disease, and the prevalence of hypertension tends to
increase with age. Current treatments for hypertension have adverse side effects and poor adherence. The purpose
of this study is to evaluate the effects of moxibustion on blood pressure in individuals with pre- or stage I
hypertension.
Methods/design: Forty-five subjects with pre- or stage I hypertension will be randomized into three groups:
treatment group A (2 times/week), treatment group B (3 times/week), and the control group (non-treated group).
The inclusion criteria will be as follows: (1) aged between 19 and 65 years; (2) prehypertension or stage I
hypertension (JNC 7, Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure); (3) the participants are volunteers and written consent obtained.
The participants in the treatment group A will undergo indirect moxibustion 2 times per week for 4 weeks, and the
participants in the treatment group B will undergo indirect moxibustion 3 times per week for 4 weeks. The
participants in the control group (non-treated group) will maintain their current lifestyle, including diet and exercise.
The use of antihypertensive medication is not permitted. The primary endpoint will be a change in patient blood
pressure. The secondary endpoints will be the body mass index, lipid profile, EuroQol and Heart Rate Variability. The
data will be analyzed with the Student’s t-test and analysis of variance (ANOVA) (p < 0.05).
Discussion: The results of this study will help to establish the optimal approach for the care of adults with pre- or
stage I hypertension.
Trial registration: Clinical Research Information Service KCT0000469
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Hypertension is an important risk factor for cardiovascu-
lar diseases including stroke, myocardial infarction, con-
gestive heart failure, kidney disease, and peripheral
vascular disease [1-3].
It is estimated that in 2025, 1.56 billion adults will
have hypertension [4]. According to the Seventh Report
of the Joint National Committee on the Prevention,
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reproduction in any medium, provided the orPressure(JNC-7), patients with a blood pressure of
120–139/80–89 mmHg have prehypertension [5]. A re-
cent study demonstrated that people with prehyperten-
sion were more likely to develop hypertension than those
with normal blood pressure over the 50-year follow-up
period [6]. According to a longitudinal population-based
US cohort study, prehypertension increases the risk of
developing cardiovascular diseases [7]. The results of an-
other study suggest that prehypertension increases the
risk of myocardial infarction, stroke, cardioplegia, and
cardiovascular death in women [8].
Moxibustion involves the application of ignited mug-
wort (Artemisia vulgaris) at acupoints or other specificd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nique is typically used to treat and prevent cold syndrome,
deficiency conditions and chronic diseases [9]. Moxibus-
tion can cause tissue damage as a result of skin irritation
or even skin burns due to the thermal stimulation, which
is performed at various temperatures. The thermal stimu-
lation can also cause inflammatory responses and vascular
changes. According to the findings of previous studies of
moxibustion, mediators such as histamine and substance
P are secreted, and this process promotes angiectasis [10].
It seems that inflammatory reactions that affect vascular
activity may ease various cardiovascular diseases, includ-
ing hypertension [11].
There are few published randomized controlled trials
(RCTs) concerning moxibustion treatment for prehy-
pertension. A systematic review on the effects of moxi-
bustion on hypertension revealed no evidence that
moxibustion is beneficial to people with hypertension.
However, the differences between specific and non-
specific effects should be examined in a future study
that includes appropriate control groups [11].Methods/design
Aims of the study
The aims of this pilot study are to evaluate the effects of
moxibustion on blood pressure in patients with pre- or
stage I hypertension, to test the methods used and to
calculate the sample size required for future randomized
trials.Design
This study will be a prospective randomized controlled
trial, and participants will be recruited from Woo-suk
University Hospital using notices at the hospital and
newspaper advertisements.
In this pilot clinical trial, patients with pre- or stage I
hypertension will be analyzed to determine the safety
and efficacy of moxibustion, and basic analysis will be
performed on the results. The study participants will
voluntarily sign clinical trial consent forms, and all
examinations and tests will be performed according to
the clinical trial plan. Eligible subjects will be chosen
based on specific inclusion and exclusion criteria. Parti-
cipants will be randomized before the first treatment.
Forty-five subjects with pre- or stage I hypertension will
be randomized into three groups: treatment group A (2
times/week), treatment group B (3 times/week), and the
control group (non-treated group). During each moxi-
bustion treatment, each acupoint will be treated five
times. The treatment will continue for 4 weeks. The
follow-up assessment is designed to evaluate the long-
term effects of moxibustion. Upon completion of the 4-
week-long treatment, follow-up tests will be conductedat weeks 8,12,16,20 and 24 after randomization
(Figure 1).
This study has been registered with the ‘Clinical Re-
search Information Service,’ Republic of Korea, which is
a registry in the WHO Registry Network (KCT0000469).
The systolic and diastolic blood pressures will be mea-
sured in the arm using an automatic blood pressure
meter (HD-505, Jawon Medical Co, Kyungsan City,
Korea). The subjects will be fitted with a BP cuff on both
arms. A trained researcher will measure the blood pres-
sure carefully in the arm with higher BP while the sub-
ject is in the seated position. The blood pressure will be
measured three times after the subject has rested for at
least 10 min. All BP measurements will be taken in a
temperature-controlled room. The three measurements
will be carried out at 5-min intervals. The mean of these
three measurements will be used in the data analysis.
The participants will be instructed not to drink caffein-
ated drinks such as coffee or tea and not to exercise,
smoke or eat 2 h before the blood pressure test. In
addition, they will be instructed to avoid drinking heavily
the day before the test [12].
The practitioner has had more than 3 years of clinical
experience since completing 6 years of study at the Col-
lege of Korean Medicine and has received a Doctor of
Korean Medicine.
Randomization
This study is designed as a pilot study to calculate the
appropriate sample size for future randomized clinical
trials. Allowing for a 20% dropout rate, each group will
include 15 participants, which is the minimum sample
size necessary to evaluate the effect of moxibustion
[13,14]. In this study, stratified randomization will be
performed by classifying subjects into age and sex by an
online centralized randomization service.
Ethics
This protocol adheres to the principles of the Declar-
ation of Helsinki and has been approved by the institu-
tional review boards of the Woo-suk University
Hospital, where the study will take place (WSOH IRB
1205-02). Before any treatment is given, written consent
will be obtained from each participant. All patients will
have the right to withdraw from the trial at any time.
Participants
Inclusion criteria were as follows: (1) aged between 19
and 65 years; (2) pre- or stage I hypertension (JNC 7);
(3) the participants are volunteers, and written consent
was obtained.
Exclusion criteria were as follows: (1) taking medi-
cations to control blood pressure; (2) secondary















at week 8, 12, 16, 20 and 24
Data collection and outcome 
Outcome assessment 




Figure 1 Flowchart of the study design.
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eases, liver diseases, thyroid gland diseases, active tu-
berculosis, or other infectious diseases; (4) diabetic
patients taking insulin or anti-diabetic medications; (5)
drug or alcohol dependence; (6) taking hemorrhagic
disease and anticoagulation medications (excluding as-
pirin); (7) receiving systemic steroid therapy or im-
munosuppressive therapy; (8) taking medications that
could affect blood pressure such as central nervous
system depressants or stimulants; (9) pregnancy or
the possibility of pregnancy; (10) hypersensitivity reac-
tions following moxibustion therapy; (11) received
oriental medicine treatment related to hypertension in
the past month; (12) participants deemed unsuitable
for the trial, as judged by the person in charge of the
clinical trial (Table 1).
Interventions
Treatment group A
The subjects receiving moxibustion treatment will be
treated 2 times per week.During each moxibustion treatment, each acupoint
will be treated five times. The moxibustion treatment
will last for 25 min. The treatment will continue for 4
weeks. Following the procedures used in several previous
studies [11,15,16], acupuncture needles will be inserted
bilaterally into three acupuncture points (LI11, ST36,
GB39) on the four peripheral extremities and unilaterally
into two points (CV4, CV12) in the abdominal region.
Indirect moxibustion (Manina, Haitnim Co., Ltd., Korea.
19 mm diameter and 21 mm height) will be used in the
trial.Treatment group B
The format will be exactly the same as those for treat-
ment group A, but the subjects receiving moxibustion
treatment will be treated three times per week.Control group (untreated group)
The control group (untreated group) will receive no
treatment. The subject in this group will be asked to
Table 1 Patient inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Aged between 19 and 65 years 1. Taking medications to control blood pressure
2. Pre- or stage 1 hypertension (JNC 7) 2. Secondary hypertension
-Systolic blood pressure between
120 and 159 mmHg
3. History of cerebrovascular disease, cardiovascular disease,
malignant tumors, kidney diseases, liver diseases,
thyroid gland diseases, active tuberculosis, or other infectious diseases
- Diastolic blood pressure between
80 and 99 mmHg
4. Diabetic patients taking insulin or anti-diabetic medications
3. The participants are volunteers and
written consent obtained
5. Drug or alcohol dependence
6. Taking hemorrhagic disease and anticoagulation medications (excluding aspirin)
7. Receiving systemic steroid therapy or immunosuppressive therapy
8. Taking medications that could affect blood pressure such as central
nervous system depressants or stimulants
9. Pregnancy or the possibility of pregnancy
10. Hypersensitivity reactions following moxibustion therapy
11. Received oriental medicine treatment related to hypertension in the past month
12. Participants deemed unsuitable for the trial, as judged by the person in
charge of the clinical trial.
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and workload.
Permitted and prohibited concomitant treatments
Brochures containing information on dietary changes,
living habits, and exercise regimens that help prevent
and alleviate hypertension will be distributed to all
groups, and the subjects will decide for themselves
whether to incorporate the suggested changes into their
daily lives.
All groups will be prohibited from undergoing active
treatment to lower the blood pressure for the duration
of their participation in this clinical trial. After the com-
pletion of the clinical trial, during the assessment period,
the subjects will be allowed to decide for themselves
whether to receive additional treatment. Any other
related information will be recorded in detail.
The use of birth control pills and central nervous sys-
tem stimulants or depressants, which can affect blood
pressure, will remain prohibited. The practitioner will be
allowed to converse with the subjects about daily care
and treatment details while carrying out the required
examination.
Outcome measures
The primary outcome measurement in this study is the
change in blood pressure before randomization (base-
line) and 4 weeks after randomization. Blood pressure
will be taken at every visit.
The secondary outcome measures will be the mean
pulse pressure, body mass index (BMI), heart rate vari-
ability (HRV), the Modified Stress Response Inventory(SRI-MF), the Pittsburgh Sleep Quality Index (PSQI),
the Fatigue Severity Scale (FSS), EuroQol (EQ-5D),
general assessments and blood tests including fasting
blood sugar (FBS), uric acid, lipid profile, high sensitivity
C-reactive protein (hs-CRP), liver function test (LFT),
hemoglobin A1c (HbA1C), and complete blood count
(CBC).
The pulse pressure refers to the difference between
the systolic pressure and the diastolic pressure. This
value reflects the degree of stiffness of the blood ves-
sels. An increase in the pulse pressure after midlife is
recognized as a risk factor for cardiovascular diseases
[17]. The BMI will be calculated, and laboratory tests
including FBS, uric acid, lipid profile, LFT, HbA1C, and
CBC will be performed before and after treatment. The
subjects will fast for 12 h before blood is drawn for
these tests. hs-CRP is an index used to assess the de-
gree of risk for cardiovascular diseases and to deter-
mine prognosis [18]. After 10 min of relaxation, the
HRV will be measured with electrodes attached to both
wrists and ankles using QECG-3 (LXC3203, Laxtha
Inc., Korea) to obtain the LF/HF ratio, TP, VLF, LF, HF,
heart rate, SDNN, RMSSD, HRV index, and PNN50.
The neck disability index (NDI) consists of ten ques-
tions: seven about whether the subject is able to per-
form functional activities, two about symptoms, and
one about concentration [19]. The EQ-5D is a ques-
tionnaire that is used to assess the quality of life [20].
The subjects mark the best answers for five questions
on mobility, self-care, pain, usual activities, and psycho-
logical status. The answers are given in the form of
numbers (1 = no problem, 2 = moderate problem, 3
Table 2 Content of baseline and follow-up questionnaires
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Blood pressure x x x
Blood test x x -
General assessment - x -
BMI (body mass index) x x x
NDI (neck disability index) x x x









of the Stress Response
Inventory)
x x x
FSS (Fatigue Severity Scale) x x x
Adverse events - x x
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reflects the subject’s health status. Global assessments
of the patients will be used to assess improvement
following the treatment, as judged by the subjects
[21]. The subjects can choose from five answers for
questions on the degree of improvement or worsening
of the blood pressure: “improved a lot,” “somewhat
improved,” “no change,” “somewhat worsened,” and
“worsened a lot.” The SRI-MF consists of 22 questions
that are related to somatization (9 items), depression
(9 items), and anger (3 items) [22]. The subjects will
mark the best answer for each of the questions based
on their experience in the past week. The assessment
is performed by adding up the scores of each item to
obtain a total score. The PSQI was used to assess the
quality of sleep and to identify sleep disorders [23].
The PSQI is an index used to assess the quality of
sleep and the presence of any sleep disorders in the
past month. This questionnaire assesses seven items:
subjective quality of sleep, latency, sleep duration, ha-
bitual sleep efficiency, factors that disturb sleep, use of
sleeping aids, and impediments to daytime function-
ing. The FSS is a questionnaire consisting of nine
items that is used to investigate the severity of fatigue
during the past week [24,25]. A Pattern Identification
questionnaire was developed specifically to determine
whether there are differences in the distributions of
the change in symptoms among the groups (Table 2).
Follow-up
Follow-up tests will be conducted at 8, 12, 16, 20 and
24 weeks after randomization. The follow-up assess-
ment is designed to evaluate the long-term effects of
moxibustion.
Statistical analysis
The results of the intention-to-treat (ITT) analysis will
be used to assess the validity of the study as a whole.
The per-protocol (PP) analysis results will be used as a
reference. The ITT analysis will be used as the main
safety assessment technique.
Continuous data will be represented by the average,
standard deviation, minimum value, and maximum
value, whereas categorical data will be represented by a
frequency table. For the comparison of the results
among the groups, the analysis of variance (ANOVA)
test will be used when the data are normally distributed;
the Kruskal-Wallis test will be used otherwise. In
addition, the chi-square test will be performed for cat-
egorical data.
After 4 weeks, the differences in systolic and diastolic
pressure will be summarized for each group using de-
scriptive statistics, including the median, average, stand-
ard deviation, and interquartile range. In addition, wewill evaluate the effectiveness of the treatment using an
analysis of covariance as the dependent variable, the
baseline score as the covariate, the group as the fixed
factor, and the hypertension stage as the stratified vari-
able. In addition, we will compare the results for the
stratified groups with the results for the whole subject
pool (non-stratified) to determine whether hypertension
stage is a suitable stratification variable. The differences
in the systolic pressure and diastolic pressure following
the treatment for each group will be analyzed using a
paired t-test or a Wilcoxon signed rank test, and the
95% confidence interval will be presented. To assess the
difference in the tendency for each visit, repeated mea-
sures analysis of variance will be performed. A signifi-
cance level of 5% will be used in all analyses.
The average pulse pressure, change in the baseline
blood pressure following the treatment, BMI, EQ-5D,
Ankle Brachial Pressure Index(ABI index), Brachial-
Ankle Pulse wave velocity(PWV index), heart rate vari-
ation (LF/HF ratio, TP, VLF, LF, HF, heart rate, SDNN,
LF norm, HF norm), and blood test results will be ana-
lyzed using the same techniques used to analyze the val-
idity of the assessment variable. To determine whether
there are differences in the distribution of the change in
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on each item using the chi-squared test.
All adverse reactions manifested will be listed with
detailed explanations. The frequency of abnormal reac-
tions that are correlated with the treatment and abnor-
mal reactions that do not have such correlations will be
recorded. A Fisher’s exact test will be performed to de-
termine whether there are any differences among the
groups with respect to the incidence of abnormal reac-
tions as reported by the subjects. Furthermore, technical
analysis will be performed to identify differences in the
degree of severity and in the type of abnormal reactions
among the groups.Adverse events
The safety evaluation will be based on adverse events,
which are expected to include blisters, redness, and
burns. Adverse reactions refer to undesirable and unin-
tentional signs (e.g., abnormal test results), symptoms or
diseases following the treatment. There does not neces-
sarily have to be a cause and effect relationship with the
treatment. The subjects will be instructed to voluntarily
report any information regarding abnormal reactions to
the practitioner on a regular basis.
Any adverse events during treatment will be recorded.
When abnormal reactions appear, the date of appear-
ance, the date of disappearance, the degree of the abnor-
mal reaction, measures taken related to the treatment,
correlation with the treatment, names of suspicious
drugs taken outside of the treatment, whether the abnor-
mal reactions were treated and any other related infor-
mation will be recorded in detail. Any medical
conditions or diseases present prior to the start of the
treatment will be considered abnormal reactions only if
they worsen after starting the treatment.
Abnormal test values or results will be considered ab-
normal reactions only if they cause clinical symptoms, if
they are considered clinically significant or if treatment
is needed.Discussion
This study is a preliminary study targeting individuals
with pre- or stage I hypertension, who will be randomly
divided into treatment group A (2 times/week), treat-
ment group B (3 times/week), and the control group
(non-treated group). Basic analysis will be performed to
assess the validity and safety of moxibustion for the
treatment of pre- or stage I hypertension. The following
results will be presented: the extent of stimulation pro-
vided by moxibustion, differences in the effect according
to the frequency of treatment, and how long the efficacy
of the treatment last. These results will be based on
long-term follow-up observation.Trial status
This trial is currently recruiting participants.
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